Biotech Values

[masterlongevity]

thats exactly correct. the data was negative and the sample size was so small that it is expected that posthoc analysis would turn up some significant results, especially when you are using these very subjective cognitive scale endpoints.

No one in the ALzheimer's throught leader community takes PBT-2 seriously. This trial finished in 2008 and they have been rehashing the data for 3 yrs trying to get a partner.

It is widely known that several companies did due diligence on PBT-2 and turned it down